Skip to content
Rheumatology Letter
  • Blog
  • About Us
  • Annals of Rheumatic Diseases
  • Current Opinion in Rheumatology
  • European Review | Rheumatology
  • Google News
  • Helio.com
  • JCR
  • Medpage
  • Medscape
  • Nature Reviews Rheumatology
  • NEJM
  • News-Medical.net | Rheumatology
  • Newsletters
  • PubMed
  • Rheumatology
  • Rheumatology Network Articles
  • RheumNow
  • Scandinavian Journal of Rheumatology
  • Science Direct
  • The Journal of Rheumatology
  • The Lancet
  • The Rheumatologist
  • Wiley
  • Blog
  • About Us
  • Annals of Rheumatic Diseases
  • Current Opinion in Rheumatology
  • European Review | Rheumatology
  • Google News
  • Helio.com
  • JCR
  • Medpage
  • Medscape
  • Nature Reviews Rheumatology
  • NEJM
  • News-Medical.net | Rheumatology
  • Newsletters
  • PubMed
  • Rheumatology
  • Rheumatology Network Articles
  • RheumNow
  • Scandinavian Journal of Rheumatology
  • Science Direct
  • The Journal of Rheumatology
  • The Lancet
  • The Rheumatologist
  • Wiley
logo
  • Home
  • 2025
  • September
  • 1
  • Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?
The Journal of Rheumatology

Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?

  • by admin
  • September 1, 2025
  • 0
  • 0
Tags:

Post navigation

Previous
Economic Factors Shape Rheumatoid Arthritis Trial Outcomes – Philanthropy News Digest
Next
Don’t miss a beat: why rheumatic heart disease, a preventable disease, still matters | Pune News

Related Post

Development of the Australian Rheumatology Association Clinical Care Standard for the Diagnosis and Management of Rheumatoid Arthritis in Adults

Patient Perspectives and Experiences With Medication for Gout: A Thematic Synthesis of Qualitative Studies

A Systematic Review of Clinical Trial Designs and Outcome Measures in Sjögren Disease Randomized Controlled Trials

Personalizing Management of Systemic Sclerosis-Associated Interstitial Lung Disease: Are Autoantibodies the Key for Risk Stratification?

Experiences With Complementary and Integrative Health Among People With Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Qualitative Study

NewsBe Made by Couponvario | Powered by WordPress